NYSEMKT: CANFCan Fite Biopharma Ltd Stock
$1.98+0.00 (+0%)
Updated Apr 22, 2024
CANF Price
$1.98
Fair Value Price
N/A
Market Cap
$8.08M
52 Week Low
$1.68
52 Week High
$3.33
P/E
-0.66x
P/B
1.29x
P/S
12.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$743.00k
Earnings
-$7.63M
Gross Margin
100%
Operating Margin
-1,027.46%
Profit Margin
-1,027.5%
Debt to Equity
0.6
Operating Cash Flow
-$8M
Beta
0.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CANF Overview
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CANF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CANF is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CANF is good value based on its book value relative to its share price (1.29x), compared to the US Biotechnology industry average (5.82x)
P/B vs Industry Valuation
CANF is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CANF due diligence checks available for Premium users.
Be the first to know about important CANF news, forecast changes, insider trades & much more!
CANF News
Valuation
CANF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.66x
Industry
16.21x
Market
41x
CANF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.29x
Industry
5.82x
CANF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CANF's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CANF's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CANF's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.0M
Liabilities
$3.7M
Debt to equity
0.6
CANF's short-term assets ($9.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CANF's short-term assets ($9.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CANF's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CANF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CANF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CANF vs Biotech Stocks
Can Fite Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.